ArticleThe Journal of clinical endocrinology and metabolism2010
Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism.
Article in The Journal of clinical endocrinology and metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02102243 (The Role of Aldosterone on Sympathetic Nerve Activity and Insulin Sensitivity), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of Aldosterone on Sympathetic Nerve Activity and Insulin Sensitivity
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Primary aldosteronism: pharmacotherapyFrontiers in endocrinology · 2025Pooled it
- Thirty-six-month results of laparoscopic-based renal denervation plus unilateral laparoscopic adrenalectomy for the treatment of patients with resistant hypertension caused by unilateral aldosterone-producing adenoma.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- Chronic renin inhibition lowers blood pressure and reduces upright muscle sympathetic nerve activity in hypertensive seniors.The Journal of physiology · 2013Trial
- Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.Hypertension (Dallas, Tex. : 1979) · 2012Trial
- Adipose Composition Before and After Primary Aldosteronism Treatment Depends on Primary Aldosteronism Subtypes and Plasma Aldosterone Concentration Before the Treatment.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Myosteatosis and sarcopenia are linked to autonomous cortisol secretion in patients with aldosterone-producing adenomas.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight.International journal of molecular sciences · 2022Review
- Reply.Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
- Primary aldosteronism is associated with risk of urinary bladder stones in a nationwide cohort study.Scientific reports · 2021Article
- Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling.The Journal of clinical endocrinology and metabolism · 2021Article
- Association of visceral adiposity and clinical outcome among patients with aldosterone producing adenoma.BMJ open diabetes research & care · 2020Article
- Adaptations in autonomic nervous system regulation in normal and hypertensive pregnancy.Handbook of clinical neurology · 2020Review
- Adrenal Tissue-Specific Deletion of TASK Channels Causes Aldosterone-Driven Angiotensin II-Independent Hypertension.Hypertension (Dallas, Tex. : 1979) · 2019Article
- Can aldosterone break your heart? Takotsubo cardiomyopathy in a patient with newly diagnosed primary aldosteronism.BMJ case reports · 2018Article
- Update on angiotensin II: new endocrine connections between the brain, adrenal glands and the cardiovascular system.Endocrine connections · 2017Review
- Classics in Cardiovascular Endocrinology: Aldosterone Action Beyond Electrolytes.Endocrinology · 2016Article
- Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Journal of cardiovascular pharmacology · 2016Review
- Reversible heart rhythm complexity impairment in patients with primary aldosteronism.Scientific reports · 2015Article
- Ambulatory Blood Pressure Monitoring-Derived Short-Term Blood Pressure Variability in Primary Aldosteronism.Journal of clinical hypertension (Greenwich, Conn.) · 2015Article
- Global- and renal-specific sympathoinhibition in aldosterone hypertension.Hypertension (Dallas, Tex. : 1979) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
contextAldosterone has been shown to exert a central sympathoexcitatory action in multiple animal models, but evidence in humans is still lacking.
objectivesOur objective was to determine whether hyperaldosteronism causes reversible sympathetic activation in humans.
methodsWe performed a cross-sectional comparison of muscle sympathetic nerve activity (SNA, intraneural microelectrodes) in 14 hypertensive patients with biochemically proven primary aldosteronism (PA) with 20 patients with essential hypertension (EH) and 18 age-matched normotensive (NT) controls. Seven patients with aldosterone-producing adenoma (APA) were restudied 1 month after unilateral adrenalectomy.
resultsMean blood pressure values in patients with PA and EH and NT controls was 145 ± 4/88 ± 2, 150 ± 4/90 ± 2, and 119 ± 2/76 ± 2 mm Hg, respectively. The major new findings are 2-fold: 1) baseline SNA was significantly higher in the PA than the NT group (40 ± 3 vs. 30 ± 2 bursts/min, P = 0.014) but similar to the EH group (41 ± 3 bursts/min) and 2) after unilateral adrenalectomy for APA, SNA decreased significantly from 38 ± 5 to 27 ± 4 bursts/min (P = 0.01), plasma aldosterone levels fell from 72.4 ± 20.3 to 11.4 ± 2.3 ng/dl (P < 0.01), and blood pressure decreased from 155 ± 8/94 ± 3 to 117 ± 4/77 ± 2 mm Hg (P < 0.01).
conclusionThese data provide the first evidence in humans that APA is accompanied by reversible sympathetic overactivity, which may contribute to the accelerated hypertensive target organ disease in this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.